Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 654

1.

Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.

Eltze E, Wild PJ, Wülfing C, Zwarthoff EC, Burger M, Stoehr R, Korsching E, Hartmann A.

Eur Urol. 2009 Nov;56(5):837-45. doi: 10.1016/j.eururo.2008.10.003. Epub 2008 Oct 11.

PMID:
18945538
[PubMed - indexed for MEDLINE]
2.

Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.

Kruck S, Sievert KD.

Eur Urol. 2009 Nov;56(5):845-6. doi: 10.1016/j.eururo.2008.10.004. Epub 2008 Oct 11. No abstract available.

PMID:
18945542
[PubMed - indexed for MEDLINE]
3.

Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.

Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L.

Eur Urol. 2009 Nov;56(5):846-7. doi: 10.1016/j.eururo.2008.10.005. Epub 2008 Oct 11. No abstract available.

PMID:
18945536
[PubMed - indexed for MEDLINE]
4.

FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.

van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A.

Eur Urol. 2007 Sep;52(3):760-8. Epub 2007 Jan 12.

PMID:
17240035
[PubMed - indexed for MEDLINE]
5.

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, Ofualuka K, Maillé P, Leroy K, Riou A, Lepage ML, Vordos D, de la Taille A, Denoux Y, Sibony M, Guyon F, Lebret T, Benhamou S, Allory Y, Radvanyi F.

J Pathol. 2012 Jul;227(3):315-24. doi: 10.1002/path.4017. Epub 2012 May 8.

PMID:
22422578
[PubMed - indexed for MEDLINE]
6.

Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival.

Wülfing C, Eltze E, Yamini J, Wülfing P, Bierer S, Böcker W, Hertle L, Semjonow A, Sievert KD.

Eur Urol. 2005 May;47(5):593-600. Epub 2005 Jan 26.

PMID:
15826749
[PubMed - indexed for MEDLINE]
7.

Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.

Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M.

Eur Urol. 2009 Nov;56(5):829-36. doi: 10.1016/j.eururo.2008.09.062. Epub 2008 Oct 9.

PMID:
18926620
[PubMed - indexed for MEDLINE]
8.

Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival.

Luo JH, Xie D, Liu MZ, Chen W, Liu YD, Wu GQ, Kung HF, Zeng YX, Guan XY.

Int J Cancer. 2008 Jun 1;122(11):2554-61. doi: 10.1002/ijc.23399.

PMID:
18246597
[PubMed - indexed for MEDLINE]
9.

Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.

Lopez-Beltran A, Alvarez-Kindelan J, Luque RJ, Blanca A, Quintero A, Montironi R, Cheng L, Gonzalez-Campora R, Requena MJ.

J Pathol. 2008 Jul;215(3):263-72. doi: 10.1002/path.2353.

PMID:
18452128
[PubMed - indexed for MEDLINE]
10.

Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder.

Santos LL, Amaro T, Pereira SA, Lameiras CR, Lopes P, Bento MJ, Oliveira J, Criado B, Lopes CS.

Eur J Surg Oncol. 2003 Feb;29(1):74-80.

PMID:
12559081
[PubMed - indexed for MEDLINE]
11.

Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN.

Eur Urol. 2011 Aug;60(2):350-7. doi: 10.1016/j.eururo.2011.05.035. Epub 2011 May 25.

PMID:
21640482
[PubMed - indexed for MEDLINE]
12.

Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.

Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI.

Br J Cancer. 2001 May 4;84(9):1242-51. Erratum in: Br J Cancer 2001 Aug 3;85(3):471.

PMID:
11336477
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.

Popov Z, Gil-Diez-De-Medina S, Ravery V, Hoznek A, Bastuji-Garin S, Lefrere-Belda MA, Abbou CC, Chopin DK.

Urol Oncol. 2004 Mar-Apr;22(2):93-101.

PMID:
15082004
[PubMed - indexed for MEDLINE]
14.

Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.

Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y.

J Urol. 2009 Jul;182(1):78-84; discussion 84. doi: 10.1016/j.juro.2009.02.125. Epub 2009 May 17.

PMID:
19447418
[PubMed - indexed for MEDLINE]
15.

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.

van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boevé ER, Jöbsis AC, Zwarthoff EC.

J Clin Oncol. 2003 May 15;21(10):1912-21.

PMID:
12743143
[PubMed - indexed for MEDLINE]
16.

Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients.

Che X, Yang D, Zong H, Wang J, Li X, Chen F, Chen X, Song X.

Urol Oncol. 2012 Jul-Aug;30(4):450-6. doi: 10.1016/j.urolonc.2010.12.016. Epub 2011 Jul 27.

PMID:
21795072
[PubMed - indexed for MEDLINE]
17.

Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up.

Wülfing P, Diallo R, Kersting C, Wülfing C, Poremba C, Rody A, Greb RR, Böcker W, Kiesel L.

Clin Cancer Res. 2003 Sep 15;9(11):4125-31.

PMID:
14519635
[PubMed - indexed for MEDLINE]
Free Article
18.

The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.

Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E.

Pathol Res Pract. 1997;193(11-12):767-75.

PMID:
9521509
[PubMed - indexed for MEDLINE]
19.

Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer.

Colquhoun AJ, Sundar S, Rajjayabun PH, Griffiths TR, Symonds RP, Mellon JK.

Clin Oncol (R Coll Radiol). 2006 Nov;18(9):702-9.

PMID:
17100158
[PubMed - indexed for MEDLINE]
20.

Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.

Liang PI, Wu LC, Sheu JJ, Wu TF, Shen KH, Wang YH, Wu WR, Shiue YL, Huang HY, Hsu HP, Chen YH, Chen LT, Li CF, Liao AC.

J Clin Pathol. 2012 Sep;65(9):802-7. doi: 10.1136/jclinpath-2012-200897. Epub 2012 Jun 9.

PMID:
22685262
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk